187 related articles for article (PubMed ID: 31125781)
1. Predictive Value of Transforming Growth Factor-α and Ki-67 for the Prognosis of Skull Base Chordoma.
Zhang S; Bai J; Li M; Zhai Y; Wang S; Liu Q; Li C; Gui S; Zhang Y
World Neurosurg; 2019 Sep; 129():e199-e206. PubMed ID: 31125781
[TBL] [Abstract][Full Text] [Related]
2. Analysis of clinical factors and PDGFR-β in predicting prognosis of patients with clival chordoma.
Zhai Y; Bai J; Wang S; Gao H; Li M; Li C; Gui S; Zhang Y
J Neurosurg; 2018 Dec; 129(6):1429-1437. PubMed ID: 29303447
[TBL] [Abstract][Full Text] [Related]
3. Clinical features and surgical outcomes of patients with skull base chordoma: a retrospective analysis of 238 patients.
Wang L; Wu Z; Tian K; Wang K; Li D; Ma J; Jia G; Zhang L; Zhang J
J Neurosurg; 2017 Dec; 127(6):1257-1267. PubMed ID: 28059654
[TBL] [Abstract][Full Text] [Related]
4. SNF5 as a prognostic factor in skull base chordoma.
Li M; Zhai Y; Bai J; Wang S; Gao H; Li C; Gui S; Du J; Zhang Y
J Neurooncol; 2018 Mar; 137(1):139-146. PubMed ID: 29222701
[TBL] [Abstract][Full Text] [Related]
5. Effect comparisons among treatment measures on progression-free survival in patients with skull base chordomas: a retrospective study of 234 post-surgical cases.
Wang L; Tian K; Ma J; Wang K; Jia G; Wu Z; Zhang L; Zhang J
Acta Neurochir (Wien); 2017 Oct; 159(10):1803-1813. PubMed ID: 28699066
[TBL] [Abstract][Full Text] [Related]
6. The utility of inflammatory biomarkers in predicting overall survival and recurrence in skull base chordoma.
Hoppe M; Gersey ZC; Muthiah N; Abdallah HM; Plute T; Abou-Al-Shaar H; Wang EW; Snyderman CH; Zenonos GA; Gardner PA
Neurosurg Focus; 2024 May; 56(5):E16. PubMed ID: 38691858
[TBL] [Abstract][Full Text] [Related]
7. C-Cbl and Cbl-b expression in skull base chordomas is associated with tumor progression and poor prognosis.
Luo P; Wang X; Zhou J; Li L; Jing Z
Hum Pathol; 2018 Apr; 74():129-134. PubMed ID: 29317233
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.
Horbinski C; Oakley GJ; Cieply K; Mantha GS; Nikiforova MN; Dacic S; Seethala RR
Arch Pathol Lab Med; 2010 Aug; 134(8):1170-6. PubMed ID: 20670138
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of a Category Based on Electron Microscopic Features of Clival Chordomas.
Bai J; Zhai Y; Wang S; Gao H; Du J; Wang J; Li M; Li C; Gui S; Zhang C; Sun Y; Zhang Y
World Neurosurg; 2017 Mar; 99():282-287. PubMed ID: 27916725
[TBL] [Abstract][Full Text] [Related]
10. High expression of survivin independently correlates with tumor progression and mortality in patients with skull base chordomas.
Ma J; Tian K; Du J; Wu Z; Wang L; Zhang J
J Neurosurg; 2019 Jan; 132(1):140-149. PubMed ID: 30641849
[TBL] [Abstract][Full Text] [Related]
11. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
12. Male sex as a risk factor for the clinical course of skull base chordomas.
Rachinger W; Eigenbrod S; Dützmann S; Simon M; Feigl GC; Kremenevskaja N; Kretzschmar H; Zausinger S; Kreth FW; Thon N; Tonn JC
J Neurosurg; 2014 Jun; 120(6):1313-20. PubMed ID: 24405075
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors in Skull Base Chordoma: A Systematic Literature Review and Meta-Analysis.
Zou MX; Lv GH; Zhang QS; Wang SF; Li J; Wang XB
World Neurosurg; 2018 Jan; 109():307-327. PubMed ID: 29045855
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, immunohistochemistry, and outcomes of 77 patients with skull base chordomas.
Ouyang T; Zhang N; Zhang Y; Jiao J; Ren J; Huang T; Chen J
World Neurosurg; 2014; 81(5-6):790-7. PubMed ID: 23298670
[TBL] [Abstract][Full Text] [Related]
15. Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.
Wang K; Tian K; Wang L; Wu Z; Ren C; Hao S; Feng J; Li J; Wan H; Jia G; Zhang L; Zhang J
Mol Med Rep; 2015 Sep; 12(3):4298-4304. PubMed ID: 26099340
[TBL] [Abstract][Full Text] [Related]
16. [Chordoma].
George B; Bresson D; Bouazza S; Froelich S; Mandonnet E; Hamdi S; Orabi M; Polivka M; Cazorla A; Adle-Biassette H; Guichard JP; Duet M; Gayat E; Vallée F; Canova CH; Riet F; Bolle S; Calugaru V; Dendale R; Mazeron JJ; Feuvret L; Boissier E; Vignot S; Puget S; Sainte-Rose C; Beccaria K
Neurochirurgie; 2014 Jun; 60(3):63-140. PubMed ID: 24856008
[TBL] [Abstract][Full Text] [Related]
17. Chordomas: Histopathological Study in View of Anatomical Location.
Cha YJ; Suh YL
J Korean Med Sci; 2019 Apr; 34(13):e107. PubMed ID: 30950252
[TBL] [Abstract][Full Text] [Related]
18. Expression of growth factors and structural proteins in chordomas: basic fibroblast growth factor, transforming growth factor alpha, and fibronectin are correlated with recurrence.
Deniz ML; Kiliç T; Almaata I; Kurtkaya O; Sav A; Pamir MN
Neurosurgery; 2002 Sep; 51(3):753-60; discussion 760. PubMed ID: 12188955
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma.
Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M
J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525
[TBL] [Abstract][Full Text] [Related]
20. The Role of EGFR, Hepatocyte Growth Factor Receptor (c-Met), c-ErbB2 (HER2-neu) and Clinicopathological Parameters in the Pathogenesis and Prognosis of Chordoma.
Tosuner Z; Bozkurt SU; Kiliç T; Yilmaz B
Turk Patoloji Derg; 2017; 33(2):112-120. PubMed ID: 28272674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
